Xian-Rui Yuan

Xian-Rui Yuan

Auto-generated profile, based on publicly available information

Xian-Rui Yuan

The Institute of Skull Base Surgery and Neurooncology at Hunan, Xiangya Hospital, Central South University, Changsha, Hunan, China

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JYJian Yuan
Jian Yuan
Gelei XiaoGelei Xiao
Gelei Xiao
GPGang Peng
Gang Peng
DLDingyang Liu
Dingyang Liu
ZWZeyou Wang
Zeyou Wang
XYXianrui Yuan
Xianrui Yuan

6 March 2010 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
CHChun-Hai Huang
Chun-Hai Huang
XLXue-Jun Li
Xue-Jun Li
YZYi-Zeng Zhou
Yi-Zeng Zhou
YLYong Luo
Yong Luo
CLCui Li
Cui Li
XYXian-Rui Yuan
Xian-Rui Yuan

18 November 2015 in Trials
Verified
Journal Article
Open access
PDF file
Rongcai JiangRongcai Jiang
Rongcai Jiang
DWDong Wang
Dong Wang
WPWai Sang Poon
Wai Sang Poon
YLYi Cheng Lu
Yi Cheng Lu
XLXin-gang Li
Xin-gang Li
JZJianning Zhang
Jianning Zhang
Chronic subdural hematoma (CSDH) is a common disease that is more prevalent in older people. Surgical intervention is a safe treatment of choice. However, the recurrence rate is relatively high and the outcome is not always satisfactory among surgically treated patients. It is believed that aberrant angiogenesis and intracapsular inflammation contribute to the development of CSDH. Atorvastatin is reported to promote angiogenesis and suppress inflammation. We have recently shown that atorvastatin is effective to non-surgically reduce and eliminate CSDH with minimal side effects. Here, we report a clinical research trial protocol that is designed to evaluate the therapeutic effects of atorvastatin on CSDH. We have designed a multi-center, randomized, placebo-controlled, double blind clinical trial for evaluating the efficacy of oral atorvastatin in reducing CSDH. We have so far recruited 96 patients with CT-confirmed or MRI-confirmed CSDHs from 16 medical centers in China. These patients were originally recruited for the Oriental Neurosurgical Evidence-based Study Team (ONET) study. After informed consent is provided, patients are randomized to receive either atorvastatin (oral 20 mg/night for 8 weeks) or placebo (dextrin for 8 weeks); and followed for 16 weeks after the treatment. The primary outcome is the change in hematoma volume at the end of 8-week treatment. Secondary outcomes include: changes in 1) the hematoma volume at the 4th, 12th, and 24th weeks; 2) Markwalder’s Grading Scale and Glasgow Coma Scale (MGS-GCS); 3) Glasgow Outcome Score (GOS) and 4) Activities of Daily Life – the Barthel Index scale (ADL-BI). Safety will be assessed during the study by monitoring adverse events, laboratory tests, electrocardiography (ECG), measurements of vital signs (temperature, pulse, and blood pressure) and body weight. Results of this trial will provide critical information regarding whether atorvastatin is an effective and safe alternative to surgical treatment of CSDH. ClinicalTrials.gov Identifier – NCT02024373 The date of trial registration: 7 August 2013

19 February 2014 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
Gelei XiaoGelei Xiao
Gelei Xiao
XYXianrui Yuan
Xianrui Yuan
JYJian Yuan
Jian Yuan
NKNadeem Akhtar Krumtally
Nadeem Akhtar Krumtally
YLYifeng Li
Yifeng Li
XDXiping Ding
Xiping Ding
In the present study, 203 patients that had previously undergone microsurgery for craniopharyngiomas (CPs) between 1992 and 2012 were analyzed retrospectively on a long‑term follow‑up basis to investigate the differences in the recurrence rate and endocrine function between patients with preserved and resected pituitary stalks. To summarize the possible outcomes of microsurgery, the 203 patients were divided into 2 groups: Group A that had preserved pituitary stalks and Group B that had undergone resections of the pituitary stalk. Tumor origins and the involvement of the pituitary stalk during surgery were observed. From 2010 onwards, an ultra‑electron microscope was used postoperatively to detect whether pituitary stalk specimens were infiltrated or invaded with tumor cells. Long‑term follow‑up observations of the patients included tumor recurrence, postoperative endocrine dysfunction and visual acuity and field. Among the 203 patients, 175 patients received gross‑total resection (GTR) (175/203, 86.2%), 28 patients underwent subtotal resection (28/203, 13.8%) and 34 patients had surgery that preserved the pituitary stalk (34/203, 16.7%). There was no significant difference in the recurrence rate between Group A (4/34, 11.8%) and the patients in Group B (10/123, 8.1%) who underwent GTR and also received follow‑ups. Of the 157 patients who were followed up, 91 individuals underwent endocrine evaluation and the outcome was divided into normal, satisfactory and poor grades. The results for Group A were 5, 18 and 0, respectively, while the results for Group B were 1, 60 and 7, respectively, which showed a statistically significant difference between the groups. Pituitary stalk specimens of 15 patients were studied postoperatively using an ultra‑electron microscope and all samples showed tumor cells had invaded the pituitary stalk (15/15, 100%). Total resections of CPs with the pituitary stalk were recommended if the pituitary stalk was intraoperatively invaded. In cases where the pituitary stalk was not involved, microsurgical excisions preserving the pituitary stalk were preferred, as there was no significant increase in the recurrence rate and the patients experienced less endocrine dysfunction.

1 June 2016 in World Neurosurgery
Verified
Journal Article
Closed access
CDCan Du
Can Du
CFCheng-Yuan Feng
Cheng-Yuan Feng
XYXian-Rui Yuan
Xian-Rui Yuan
QLQing Liu
Qing Liu
ZPZe-Feng Peng
Ze-Feng Peng
TXTao Xiong
Tao Xiong

11 March 2016 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
CDCan Du
Can Du
CFCheng-Yuan Feng
Cheng-Yuan Feng
JYJian Yuan
Jian Yuan
XYXianrui Yuan
Xianrui Yuan